视网膜色素性变

Professor

Casey Eye Institute

Oregon Health and Sciences University

Portland

OR

利益声明

MEP serves on the scientific advisory board and executive committee for the Foundation Fighting Blindness.

Associate Professor

Casey Eye Institute

Oregon Health and Sciences University

Portland

OR

利益声明

PY acted as a consultant for Applied Genetic Technologies Corp in 2019 and was paid for a meeting regarding XLRP gene therapy, for which there was no agreement to disseminate information.

Dr Mark E. Pennesi and Dr Paul Yang would like to gratefully acknowledge Dr Richard G. Weleber and Dr Peter J. Francis, previous contributors to this topic.

利益声明

RGW has served as a consultant to Novartis, Pfizer, and Wellstat, is a member of the scientific advisory board for Applied Genetic Technologies Corp, and serves on the scientific advisory board for the Foundation Fighting Blindness (the relationship has been reviewed and managed by Oregon Health & Science University). RGW also reports having received grants and personal fees from the Foundation Fighting Blindness and Applied Genetic Technologies Corp, and other support from Sanofi-Fovea, all outside the submitted work. In addition, RGW has a patent (US patent 8,657,446, Method and apparatus for visual field monitoring, also known as Visual Field Monitoring and Analysis, or VFMA, which has not been issued). PJF declares that he has no competing interests.

Consultant Ophthalmologist

Sunderland Eye Infirmary

Sunderland

UK

利益声明

SF declares that he has no competing interests.

Professor of Ophthalmology

Director

Center for Genetic Eye Diseases

Cole Eye Institute

Cleveland Clinic

Cleveland

OH

利益声明

ET declares that he has no competing interests.